# US 6,726,896 B2 · Stool marker

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,726,896 B2
- Document ID: US6726896B2
- Status: Granted
- Kind: B2
- Application number: 09/800,076
- Filed: 2001-03-05
- Published: 2001-11-01
- Granted: 2004-04-27
- Earliest claimed: 2000-03-07
- Inventors: Kevin Tait
- Web page: https://patentgrep.com/patent/US6726896B2

## CPC

- A61K 33/08: Oxides; Hydroxides
- A61K 31/00: Medicinal preparations containing organic active ingredients
- A61K 33/18: Iodine; Compounds thereof
- A61K 33/24: Heavy metals; Compounds thereof
- A61K 33/243: Platinum; Compounds thereof
- A61K 33/26: Iron; Compounds thereof
- A61K 33/242: Gold; Compounds thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A stool marker formulation for oral administration and suitable for use in CT Colography including a material adapted to provide marked stool which has a modified response to radiation relative to unmarked stool. Radiologically scanning the colon of a patient treated to produce marked stool produces data which can be manipulated to provide a representation of the colon including where present, a polyp. The active ingredient is preferably barium sulfate which has been destabilised to reduce its resistance to flocculation.

## Claims

### Claim 1

A liquid stool marker formulation which renders stool opaque to radiation in CT colography, said formulation comprising:
from 0 to less than 0.035N ionic dispersants;
0.5 to 3% w/v barium sulfate; and
a flocculant to flocculate said radio opacifying agent, wherein 20 g of said liquid formulation diluted with water to 50 ml and titrated against 3.0% w/v ferrous sulfate at pH5.0-5.5 has a flocculation resistance of less than 5 ml.

### Claim 2 (depends on 1)

A liquid stool marker formulation according to claim 1 wherein the barium sulfate and is administered in an amount less than 7.5 g per dose.

### Claim 3 (depends on 1)

A liquid stool marker formulation according to claim 1 wherein barium sulfate is present in an amount of 5 g per dose.

### Claim 4 (depends on 3)

A liquid stool marker formulation according to claim 3 wherein the barium sulfate is present in an amount greater than 1 g per dose.

### Claim 5 (depends on 1)

A liquid stool marker formulation according to claim 1 wherein the barium sulfate has a particle size of about 3 microns.

### Claim 6 (depends on 1)

A liquid stool marker formulation according to claim 1 wherein the flocculant is smectite clay.

### Claim 7 (depends on 1)

A liquid stool marker formulation according to claim 1 further including a viscosity modifier which does not behave as a protective colloid in respect of the material to render stool opaque to radiation.

### Claim 8 (depends on 1)

A liquid stool marker formulation according to claim 1 further including an anti-caking agent.

### Claim 9 (depends on 1)

A liquid stool marker formulation according to claim 1 further treated with a treatment selected from the group consisting of high shear stirring and sonification prior to administration to a patient.

### Claim 10 (depends on 1)

A liquid stool marker formulation according to claim 1 wherein the material to render stool opaque to radiation is present in an amount effective to differentiate stool from non-stool without rendering density or movement induced artefacts in a CT rendering of the stool.

### Claim 11 (depends on 1)

A liquid stool marker formulation according to claim 1 including (% by weight):
Barium Sulfate 1.2% Citric Acid Anhydrous 0.03% Hydroxypropyl methylcellulose 0.45% Smectite Clay 0.75% Flavour, Sweetener, Preservatives q.s. Water q.s. 100%.

### Claim 12 (depends on 1)

A liquid stool marker formulation according to claim 1 prepared from a solid composition.

### Claim 13 (depends on 1)

A method of radiologically visualising the colon of a patient including the steps of:
orally administering to a patient a stool marker formulation according to claim 1 to render stool opaque to radiation;
radiologically scanning the colon of the patient to produce data; and
manipulating the data to determine that portion of the data due to marked stool, to thereby provide a representation of the colon, including where present, a polyp.

### Claim 14 (depends on 13)

A method according to claim 13 wherein the radiological visualisation is by means of a CT scanner.

### Claim 15 (depends on 13)

A method according to claim 13 wherein the radiological visualisation is by means of a helical scanner.

### Claim 16 (depends on 13)

A method according to claim 13 wherein the manipulation of the data involves subtraction of that portion of the data due to the marked stool, leaving a representation of the colon, including where present a polyp.

### Claim 17 (depends on 1)

A method of preparing a patient for a radiological examination including the step of administering to the patient a formulation according to claim 1 to render stool opaque to radiation.

### Claim 18 (depends on 13)

A method according to claim 13 wherein the formulation is administered orally over 24 to 48 hours preceding the radiological examination.

### Claim 19 (depends on 13)

A method according to claim 13 wherein the formulation is administered in four or more dosages over 24 to 48 hours preceding the radiological examination.
